0001415889-25-024271.txt : 20250911 0001415889-25-024271.hdr.sgml : 20250911 20250911160722 ACCESSION NUMBER: 0001415889-25-024271 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250909 FILED AS OF DATE: 20250911 DATE AS OF CHANGE: 20250911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stueland Katherine CENTRAL INDEX KEY: 0001689575 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39482 FILM NUMBER: 251308605 MAIL ADDRESS: STREET 1: 458 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GeneDx Holdings Corp. CENTRAL INDEX KEY: 0001818331 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 851966622 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 6TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 888-729-1206 MAIL ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 6TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Sema4 Holdings Corp. DATE OF NAME CHANGE: 20210721 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences, Inc. DATE OF NAME CHANGE: 20200715 4 1 form4-09112025_080917.xml X0508 4 2025-09-09 0001818331 GeneDx Holdings Corp. WGS 0001689575 Stueland Katherine C/O GENEDX HOLDINGS CORP. 333 LUDLOW ST., NORTH TOWER, 6TH FLOOR STAMFORD CT 06902 true true false false Chief Executive Officer 0 Class A Common Stock 2025-09-09 4 M 0 6546 0 A 9986 D Class A Common Stock 2025-09-09 4 S 0 3639 128.0500 D 6347 D Class A Common Stock 2025-09-09 4 S 0 18 129.0790 D 6329 D Restricted Stock Unit 2025-09-09 4 M 0 6546 0 D Class A Common Stock 6546 32733 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Following the reported sales, in addition to the 6,329 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 463,289 shares of Class A common stock and options to purchase up to an aggregate of 107,610 shares of Class A common stock, which RSUs and options vest according to their respective terms. 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. /s/ Bridget Brown, Attorney-in-Fact 2025-09-11